Abstract Number: 1691 • ACR Convergence 2025
Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk of low bone mineral density, with studies showing a 40% frequency of osteopenia (Lilleby,…Abstract Number: 1549 • ACR Convergence 2025
Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
Background/Purpose: Inflammatory arthritis is a cardinal manifestation of systemic lupus erythematosus (SLE), limiting joint mobility and adversely affecting quality of life.1 Joint activity in SLE…Abstract Number: 1530 • ACR Convergence 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…Abstract Number: 1512 • ACR Convergence 2025
Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Background/Purpose: With the introduction of anifrolumab to clinical practice, there is a growing interest in identifying factors associated with IFN activity in patients with SLE.…Abstract Number: 1489 • ACR Convergence 2025
Impact of Menopause on Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
Background/Purpose: Women of childbearing age are more prone to developing autoimmune diseases, suggesting a role for sex hormones, particularly estrogens, in regulating both cellular and…Abstract Number: 1472 • ACR Convergence 2025
Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort
Background/Purpose: LLDAS is a desirable state in lupus, with ongoing global reports on its durability and outcomes. The relationship between LLDAS, baseline characteristics, and drug…Abstract Number: 1284 • ACR Convergence 2025
Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in juvenile-onset systemic lupus erythematosus (jSLE) patients. We aimed to assess the…Abstract Number: 1106 • ACR Convergence 2025
Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy is a progressive, vision-threatening retinal disease. While HCQ is typically discontinued after toxicity is detected, some patients undergo tapering due to…Abstract Number: 0981 • ACR Convergence 2025
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…Abstract Number: 0927 • ACR Convergence 2025
Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
Background/Purpose: Lupus is a chronic autoimmune disease with a global loss of self-tolerance. Lupus patients are photosensitive where exposure to even ambient sunlight results in…Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…Abstract Number: 0637 • ACR Convergence 2025
DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that disproportionately affects individuals of Amerindian ancestry and those who self-identify as Hispanic. The term “Hispanic”…Abstract Number: 0619 • ACR Convergence 2025
Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Background/Purpose: SLE patients are at increased risk of infections, including herpes zoster (HZ). Prior studies evaluating the recombinant herpes zoster vaccine (RZV) in SLE have…Abstract Number: 0602 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Background/Purpose: Limited information is available about the effect of systemic lupus erythematosus (SLE) on healthcare resource utilization and healthcare expenditures. The associations between SLE and…Abstract Number: 0825 • ACR Convergence 2025
Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules
Background/Purpose: Internal medicine (IM) residents often receive limited rheumatology training, contributing to low confidence in managing rheumatologic conditions and suboptimal performance on standardized examinations. Virtual…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 181
- Next Page »
